HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study

Several retrospective epidemiological studies report that utilization of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors called statins at mid-life can reduce the risk of developing sporadic Alzheimer’s disease (AD) by as much as 70%. Conversely, administration of these inhibitors in cli...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Psychiatry
Asıl Yazarlar: Leduc, Valerie, De Beaumont, Louis, Théroux, Louise, Dea, Doris, Aisen, Paul, Petersen, Ronald C., Dufour, Robert, Poirier, Judes
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4318698/
https://ncbi.nlm.nih.gov/pubmed/25023145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mp.2014.81
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller